Stonepine Capital Management LLC Makes New Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Stonepine Capital Management LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 20,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,128,000. ANI Pharmaceuticals accounts for 0.9% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 28th biggest position. Stonepine Capital Management LLC owned about 0.10% of ANI Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ANIP. Barclays PLC raised its stake in ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after purchasing an additional 135,003 shares in the last quarter. Franklin Resources Inc. boosted its holdings in ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock valued at $705,000 after acquiring an additional 691 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in ANI Pharmaceuticals by 67.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company’s stock valued at $17,226,000 after acquiring an additional 125,438 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $544,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after buying an additional 310 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the completion of the sale, the insider now owns 107,317 shares of the company’s stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. This trade represents a 1.44% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,681 shares of company stock valued at $468,698. 11.10% of the stock is owned by insiders.

Analyst Ratings Changes

ANIP has been the topic of a number of analyst reports. Guggenheim reiterated a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $80.13.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $59.99 on Friday. The stock has a market cap of $1.31 billion, a PE ratio of -109.07 and a beta of 0.56. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $77.00. The stock has a fifty day simple moving average of $66.91 and a 200-day simple moving average of $60.77.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals’s revenue was up 43.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.82 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.